Alternative names:
SARS-CoV-2 Alpha variant

Specifications for
PepTivator
®
SARS-CoV-2 Prot_N B.1.1.7

Overview

PepTivators are pools of lyophilized peptides, consisting mainly of 15-mer sequences with 11 amino acids overlap. The PepTivator
®
SARS-CoV-2 Prot_N B.1.1.7 Mutation Pool covers selectively the mutated regions in the nucleocapsid phosphoprotein (“N”) of the SARS-CoV-2 B.1.1.7 lineage (Alpha variant). PepTivator SARS-CoV-2 Prot_N B.1.1.7 WT Reference Pool consists of the 9 homologous peptides of the Wuhan sequence and serves as a control.
In vitro
stimulation of antigen-specific T cells with PepTivator Peptide Pools causes the secretion of effector cytokines and the up-regulation of activation markers, which then allow the detection and isolation of antigen-specific T cells.

Alternative names

SARS-CoV-2 Alpha variant

Detailed product information

Background information

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) was first detected in December 2019 in Wuhan, China. Since that time the virus kept mutating, leading to new virus variants. The B.1.1.7 lineage, also known as Alpha variant, VUI202012/01 or VOC202012/01, is a SARS-CoV-2 variant that was first discovered in Kent, UK in September 2020. The mutations of this variant affect also immune relevant parts of structural SARS-CoV-2 proteins and the respective sequences are available in GISAID, a genome data base, e.g. reference sequence EPI_ISL_756151. The B.1.1.7 lineage (Alpha variant) has been found to be more infectious than former variants and has become quickly the dominant strain in the UK.
In total there are 4 mutations in the nucleocapsid phosphoprotein (“N”) of the B.1.1.7 lineage (Alpha variant) compared to the Wuhan variant (reference genome GenBank MN908947.3): D3L, R203K, G204R, S235F.
PepTivator
®
SARS-CoV-2 Prot_N B.1.1.7 Mutation Pool covers selectively the mutated regions. It consists of 9 peptides of mainly 15 aa length. The PepTivator SARS-CoV-2 Prot_N B.1.1.7 Mutation Pool can be used to supplement PepTivators covering the sequence of the wild-type nucleocapsid phosphoprotein (“N”) in order to detect immune responses towards both variants, Wuhan (wild-type) variant and B.1.1.7 lineage (Alpha variant). A PepTivator Peptide pool spanning the complete sequence of the nucleocapsid phosphoprotein (“N”) of the Wuhan (wild-type) variant is PepTivator SARS-CoV-2 Prot_N.
PepTivator SARS-CoV-2 Prot_N B.1.1.7 WT Reference Pool consists of the 9 homologous peptides of the Wuhan sequence and covers D3, R203, G204, S235 of the Wuhan variant (reference genome GenBank MN908947.3). PepTivator SARS-CoV-2 Prot_N B.1.1.7 WT Reference Pool serves as a control for the PepTivator SARS-CoV-2 Prot_N B.1.1.7 Mutation Pool. Comparison of the T cell immune response upon stimulation with mutation and reference pool can be used to analyze mutation-specific T cell responses.

Applications

The
in vitro
stimulation of SARS-CoV-2–specific CD4
+
and CD8
+
T cells with PepTivators causes secretion of effector cytokines and upregulation of activation markers, which then allow the detection and isolation of SARS-CoV-2–specific T cells:
  • Detection and analysis of antigen-specific CD4+ and CD8+ effector/memory T cells in PBMCs by MACS® Cytokine Secretion Assays, intracellular cytokine staining, or other technologies.
  • Isolation of viable antigen-specific CD4+ T cells with the CD154 MicroBead Kit, or of viable CD4+ and CD8+ T cells using MACS Cytokine Secretion Assay – Cell Enrichment and Detection Kits. Subsequently, cells can be expanded for generation of T cell lines.
  • Generation antigen-specific CD4+ and CD8+ effector/ memory T cells from naive T cell populations.
  • Pulsing of antigen-presenting cells, e.g. for research on dendritic cell vaccination.

Resources for
PepTivator
®
SARS-CoV-2 Prot_N B.1.1.7

Related products for
PepTivator
®
SARS-CoV-2 Prot_N B.1.1.7

4 products available